(Total Views: 71)
Posted On: 10/11/2019 10:35:34 AM
Post# of 74551
$GTBP ~ GT Biopharma recently announced the sale of their fixed dose combination Tablet (GTB-004) for Myasthenia Gravis (Chronic Autoimmune Disease) to DAS Therapeutics >>
https://www.barchart.com/story/stocks/quotes/...erapeutics
Under the terms of the Asset Purchase Agreement, DAS Therapeutics acquires all rights, title, clinical data, composition-of-matter and use patents related to GTB-004. GT Biopharma will receive a $200,000 up-front payment, annual royalties of 1.5% of Net Yearly Sales, and a $6 million payment based on achievement of commercial milestone.
https://www.barchart.com/story/stocks/quotes/...erapeutics
Under the terms of the Asset Purchase Agreement, DAS Therapeutics acquires all rights, title, clinical data, composition-of-matter and use patents related to GTB-004. GT Biopharma will receive a $200,000 up-front payment, annual royalties of 1.5% of Net Yearly Sales, and a $6 million payment based on achievement of commercial milestone.
(0)
(0)
